Followers | 91 |
Posts | 3296 |
Boards Moderated | 0 |
Alias Born | 10/18/2010 |
Tuesday, June 30, 2020 6:40:58 PM
Last but not least, we come across Moderna, which has grabbed headlines left and right as a result of its experimental COVID-19 vaccine, mRNA-1273.
Representing Piper Sandler, 5-star analyst Edward Tenthoff has high hopes based on early data. After MRNA published a preprint of mRNA-1273 preclinical data while simultaneously under peer-review for publishing in a leading medical journal, the analyst tells investors that the data suggests “mRNA-1273 supports clinical activity in humans.”
“mRNA-1273 formulated in lipid nanoparticles elicited a balance both humoral (antibody) and cellular (CD8 T cell) immunity. Mice immunized with 0.0025-20mcg of mRNA-1273 demonstrated strong dose-dependent correlation between binding and neutralizing antibody responses. Importantly, mice receiving two 1.0mcg doses of mRNA-1273 were completely protected from viral replication in lungs and nasal cavities after re-challenge at 5- and 13-weeks following boost,” Tenthoff explained.
Looking more closely at the candidate, it targets a pre-fusion Spike protein stabilized by two proline substitutions. This is important as it could allow for a more generalizable approach to be used to protect against mutations.
It should also be noted that the Phase 2 study of mRNA-1273 has already enrolled 300 healthy adults aged 18-55 years, and 50 out of 300 subjects over the age of 55. According to Tenthoff, the data from this study should “further validate safety and efficacy of the 100µg dose in a broader population, which was selected for the Phase 3 trial.” This trial is set to kick off in July.
Tenthoff added, “Lonza will support manufacturing of 500 million-1 billion doses per year. mRNA-1273 holds Fast Track Designation.”
Based on all of the above, it’s no wonder Tenthoff reiterated his Overweight rating. With a $100 price target, shares could gain 61% in the next twelve months. (To watch Tenthoff’s track record, click here)
Looking at the consensus breakdown, other analysts are on the same page. With 11 Buys and 2 Holds, the word on the Street is that MRNA is a Strong Buy. The $87.64 average price target puts the upside potential at 42%. (See Moderna stock-price forecast on TipRanks)
Recent MRNA News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 11:05:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:08:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/15/2024 03:44:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/09/2024 08:34:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2024 07:28:01 PM
- Apple Joins OpenAI Board, Logitech President Opts Out of Reelection, and More News • IH Market News • 07/03/2024 10:59:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:59 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 04:45:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:05:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/10/2024 07:16:06 PM
- Apple Showcases AI at WWDC 2024, Nvidia Stock Split Starts Today, and More News • IH Market News • 06/10/2024 11:29:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:27:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:20:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/04/2024 09:12:54 PM
- Economic Worries May Lead To Weakness On Wall Street • IH Market News • 06/04/2024 01:10:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:36:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:20:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 07:11:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:36:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:27:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:14:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 08:16:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 08:12:34 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 07:22:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/29/2024 07:20:31 PM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM